Zobrazeno 1 - 10
of 11
pro vyhledávání: '"I Castañeda Macias"'
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::905310101c92b25e5de4517964bed627
https://doi.org/10.1136/ejhpharm-2022-eahp.334
https://doi.org/10.1136/ejhpharm-2022-eahp.334
Autor:
J Cordero Ramos, I Castañeda Macias, M Vázquez-Real, L Rendón de Lope, M Murillo Izquierdo, C Castillo Martin
Publikováno v:
Section 6: Education and Research.
Background Alemtuzumab is a humanised monoclonal antibody against CD52 approved for relapsing-remitting multiple sclerosis (RRMS), which is a progressive illness affecting the central nervous system (CNS). Purpose The objective of the present study w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::641e0537802eb057a30463b10108b8e8
https://doi.org/10.1136/ejhpharm-2019-eahpconf.609
https://doi.org/10.1136/ejhpharm-2019-eahpconf.609
Autor:
I Castañeda Macias, S Sandoval Fernandez del Castillo, Alvarado Fernández, M Murillo Izquierdo, L Jiménez Guerrero
Publikováno v:
Drug information and pharmacotherapy.
Background Canakinumab is a IgG1 anti-interleukin-1β monoclonal antibody indicated in the treatment of Muckle–Wells syndrome (MWS). It is an autosomal dominant congenital disease that is considered a rare disease. Hives, joint pains, conjunctiviti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6beb2914f5d2aae6a7853733a7dac261
https://doi.org/10.1136/ejhpharm-2017-000640.327
https://doi.org/10.1136/ejhpharm-2017-000640.327
Autor:
I Castañeda Macias, M Vazquez Real, S Sandoval Fernandez del Castillo, M Murillo Izquierdo, L Jiménez Guerrero
Publikováno v:
General management.
Background We describe a 47-year-old women diagnosed with C3 category HIV infection in 1996. After other drug combinations, she started on LPV/r (a protease inhibitor (PI)) in 2007 and in 2013 she had a DDD pacemaker implanted. Purpose To explore whe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::910a6756923f79e76753d81d4f81cdfa
https://doi.org/10.1136/ejhpharm-2017-000640.373
https://doi.org/10.1136/ejhpharm-2017-000640.373
Autor:
I Castañeda Macias, J Cordero Ramos, MC Donoso Rengifo, S Santana Martínez, M Murillo Izquierdo
Publikováno v:
Drug information and pharmacotherapy.
Background Idiopathic pulmonary fibrosis (IPF) is a specific type of chronic fibrosing interstitial pneumonia. Nintedanib is a tyrosine kinase inhibitor which has been approved for the clinical treatment of IPF in adults. Purpose To evaluate the effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3727cc7d481d6431a300d3d12c64bfd
https://doi.org/10.1136/ejhpharm-2017-000640.259
https://doi.org/10.1136/ejhpharm-2017-000640.259
Autor:
C Donoso Rengifo, L Jiménez Guerrero, S Sandoval Fernandez del Castillo, M Nuñez Nuñez, I Castañeda Macias, M Murillo Izquierdo
Publikováno v:
Drug information and pharmacotherapy.
Background The δ-9-tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray (Sativex) is a standardised cannabinoid based medicine for add on treatment of resistant multiple sclerosis (MS) induced spasticity. Purpose To evaluate the use of oromuc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4987968630a7a07694f30836192190e3
https://doi.org/10.1136/ejhpharm-2017-000640.249
https://doi.org/10.1136/ejhpharm-2017-000640.249
Autor:
L Abdel-Kader Martín, I Castañeda Macias, J Martinez Turrion, MI Sierra Torres, M Vazquez Real, LL Poyatos Ruiz
Publikováno v:
European Journal of Hospital Pharmacy. 23:A102.2-A103
Background In phase 1, 2 and 3 trials of nab-paclitaxel, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted an observational study to assess the effectiveness and safety of this therapy in real clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13ca8ce1a0ae0a81d04bde4b50c2502c
https://doi.org/10.1136/ejhpharm-2016-000875.232
https://doi.org/10.1136/ejhpharm-2016-000875.232
Autor:
Donoso Rengifo, L Jiménez Guerrero, Alvarado Fernández, M Vázquez-Real, E Romero Carreño, I Castañeda Macias, S Santana Martínez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A159.2-A160
Background Benzodiazepines (BZD) have to be reconciled within 24 h of admission to avoid withdrawal symptoms. On the other hand, it’s important to check the discharge report to avoid treatment discrepancies. Purpose To find out the accuracy of BZD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccbcc1e15f3da64b069dcc1b2a2a6ae6
https://doi.org/10.1136/ejhpharm-2015-000639.384
https://doi.org/10.1136/ejhpharm-2015-000639.384
Autor:
A Maria Dolores, I Castañeda Macias, M Vázquez-Real, MC Donoso Rengifo, C Meneses Mangas, M Moya-Martin, Sara Santana
Publikováno v:
European Journal of Hospital Pharmacy. 22:A35.2-A35
Background Surgical patients are especially susceptible to nutritional disorders; additionally an adequate nutritional status is important in achieving prompt recovery. Purpose To describe and analyse possible shortcomings related to nutritional stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2842ddbd750ec3046e9ea56aa77044c0
https://doi.org/10.1136/ejhpharm-2015-000639.84
https://doi.org/10.1136/ejhpharm-2015-000639.84
DI-081 Oral chemotherapy: incidence and description of potential interactions between drugs and food
Autor:
L Jiménez Guerrero, S Santana Martínez, JA Marcos Rodríguez, I Castañeda Macias, Alvarado Fernández, C Donoso Rengifo
Publikováno v:
European Journal of Hospital Pharmacy. 22:A106.1-A106
Background Oral chemotherapy is increasingly used in Oncology. It has important advantages, such as patient comfort, but it also brings new challenges which did not exist with the intravenous treatment. Some of these drugs have interactions with food
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b61e568451f2042b1bf31668e336feb2
https://doi.org/10.1136/ejhpharm-2015-000639.255
https://doi.org/10.1136/ejhpharm-2015-000639.255